NEW YORK, Jan 3 (Reuters) - The healthcare reform bill currently winding its way through the U.S. Congress may make the shares of some health and drug companies more attractive, Barron's wrote in its Jan. 4 edition.
Stocks in the healthcare sector are trading at discounts even though the final version of the Obama administration's proposed reform represents less of an important change than expected, the financial weekly wrote, citing Rockefeller & Co analyst David Song.
Most healthcare companies will benefit from the incentive the bill gives providers to give more care, Barron's wrote.
For example, diagnostic-testing company Laboratory Corp of America may be priced conservatively, Barron's wrote.
Drugmakers Amgen, which has a new pill for osteoporosis, and Alexion Pharmaceuticals, which has an approved drug for a rare blood disorder, should both gain from certain provisions of the Senate bill dealing with marketing exclusivity, Barron's wrote, citing Song.
(Reporting by Phil Wahba; Editing by Steve Orlofsky) Keywords: HEALTHSTOCKS/ (phil.wahba@thomsonreuters.com; +1 646 223 6128; Reuters Messaging: phil.wahba.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Stocks in the healthcare sector are trading at discounts even though the final version of the Obama administration's proposed reform represents less of an important change than expected, the financial weekly wrote, citing Rockefeller & Co analyst David Song.
Most healthcare companies will benefit from the incentive the bill gives providers to give more care, Barron's wrote.
For example, diagnostic-testing company Laboratory Corp of America may be priced conservatively, Barron's wrote.
Drugmakers Amgen, which has a new pill for osteoporosis, and Alexion Pharmaceuticals, which has an approved drug for a rare blood disorder, should both gain from certain provisions of the Senate bill dealing with marketing exclusivity, Barron's wrote, citing Song.
(Reporting by Phil Wahba; Editing by Steve Orlofsky) Keywords: HEALTHSTOCKS/ (phil.wahba@thomsonreuters.com; +1 646 223 6128; Reuters Messaging: phil.wahba.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.